Clik here to view.
Will a U.S.-India Working Group do the Bidding of the Pharma Industry?
Source: Wall Street Journal After a meeting last week between President Barack Obama and the recently elected Indian Prime Minister Narendra Modi, the White House issued a statement that included a...
View ArticleClik here to view.
USTR launched Out of Cycle Review for India
USTR has today launched an Out-of-Cycle Review for India, per this year’s Special 301 Report. USTR is accepting public comments until October 31st. (Interesting to note that it is only a two week...
View ArticleClik here to view.
Modi’s chief economic adviser Arvind Subramanian had opposed India on IPR...
Source: Times of India NEW DELHI: The man who has been appointed the chief economic adviser to the government of India, Arvind Subramanian, was until recently urging the US to initiate disputes against...
View ArticleClik here to view.
Letter to the Prime Minister: Why the new Indo-US ‘Bilateralism’ on...
Several organisations and individuals from across India have collectively sent a letter to the Prime Minister, Shri Narendra Modi, expressing their concerns on the Joint Working Group on Intellectual...
View ArticleClik here to view.
US asked not to pressurise India to reject cancer drug license
Source: Hindu An international organisation working for cancer-affected people has asked the Obama administration not to pressurise India to reject a compulsory license on a drug for a rare form of...
View ArticleClik here to view.
South Centre concerned over US pressure on India’s IP regime
Source: TWN Geneva, 11 Nov (Kanaga Raja) — The South Centre has expressed concern over the pressures being placed on India by the United States Trade Representative (USTR) through the out-of-cycle...
View ArticleClik here to view.
If US had a patent law like ours, they would discover many more drugs: Anand...
Source: The Times of India 8 Dec 2014 India’s intellectual property (IP) law has been hailed as one of the most progressive for safeguarding public interest, and several nations like Argentina, the...
View ArticleClik here to view.
Trade Group Wants to See Stricter Limits on Compulsory Licensing
Source: RAPS 4 Mar 2015 A US-based trade group wants to see the United States Trade Representative (USTR) pursue stricter limits on the ability of countries to bypass patent protection. In its Special...
View ArticleClik here to view.
US pharma body slams Indian patent regime
Rupali Mukherjee, TNN | Feb 9, 2016 Mumbai: Criticizing India’s “weak” intellectual property rights (IPR) regime, PhRMA (Pharmaceutical Research and Manufacturers of America), which represents leading...
View ArticleClik here to view.
PhRMA Special 301 submission 2016
PhRMA Special 301 Submission 2016 insists that India remains on the Priority Watch List in the USTR Special 301 Report. PhRMA sees India’s progressive Patent Act of 2005 and IP environment as a legal...
View ArticleClik here to view.
Eli Lilly bats for a favourable patent regime in India
Eli Lilly wants a more favourable patent regime that ‘rewards innovation’ and would welcome an open dialogue from the government in this respect New Delhi: Global pharma company Eli Lilly wants a more...
View ArticleClik here to view.
Compulsory licensing: India gave ‘private reassurance’, says US business council
In a review submitted to USTR, four US industry bodies have said that India has developed a “positive” approach over the compulsory licensing issue. Written by Liz Mathew, The Indian Express | New...
View ArticleClik here to view.
U.S. industry body says India agreed to not issue ‘compulsory’ drug licences
By Zeba Siddiqui, Reuters|March 9, 2016 India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western...
View ArticleClik here to view.
Nothing Special (301) to report
The annual IP report is expected soon By KM Gopakumar, The Hindu BusinessLine The Special 301 Report, an annual feature from the US that evaluates global intellectual property (IP) protection and...
View ArticleClik here to view.
US Special 301 inconsistent with WTO rules, says India
Source: Hindu BusinessLine | APRIL 25, 2016 India has said that the US Special 301 report, which tries to put pressure on countries to enhance their intellectual property rights (IPRs) legislation,...
View ArticleClik here to view.
On IP Protection, USTR Finds Fault With China, India … And Switzerland?
BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns...
View ArticleClik here to view.
US continues to keep India on intellectual property priority watch list
By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of...
View ArticleClik here to view.
Indian pharma at odds with US trade group over USTR Priority Watch List
The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List –...
View ArticleClik here to view.
Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay...
In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted...
View ArticleClik here to view.
US continue to bully India – Place India again in Special 301 Priority Watch...
Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders...
View Article